PMID- 35096256
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220201
IS  - 1941-2789 (Print)
IS  - 2689-9175 (Electronic)
IS  - 1941-2789 (Linking)
VI  - 14
IP  - 12
DP  - 2021 Dec
TI  - Review on Novel Oral Therapies for Psoriasis.
PG  - 55-63
AB  - Currently, several classes of oral therapies for psoriasis are in use, in 
      development, or in investigative stages. Standard non-biologic treatments for 
      psoriasis, such as methotrexate, cyclosporine, and acitretin, have generally 
      unfavorable safety profiles and are not ideal for long-term use. This review will 
      address the safety and efficacy of existing and novel oral therapies for 
      psoriasis that target inflammatory pathways via modulation of phosphodiesterase 4 
      (PDE4), Janus kinases (JAKs), sphingosine 1-phosphate (S1P), A3 adenosine 
      receptors, and rho-associated kinase 2 (ROCK2), with an emphasis on JAK 
      inhibitors.
CI  - Copyright (c) 2021. Matrix Medical Communications. All rights reserved.
FAU - Marushchak, Olga
AU  - Marushchak O
AD  - Ms. Marushchak and Dr. Goldenberg are with the Icahn School of Medicine at Mount 
      Sinai in New York, New York.
AD  - Ms. Rose Yakubov and Ms. Rebecca Yakubov are with McMaster University in 
      Hamilton, Ontario, Canada.
FAU - Yakubov, Rose
AU  - Yakubov R
AD  - Ms. Marushchak and Dr. Goldenberg are with the Icahn School of Medicine at Mount 
      Sinai in New York, New York.
AD  - Ms. Rose Yakubov and Ms. Rebecca Yakubov are with McMaster University in 
      Hamilton, Ontario, Canada.
FAU - Yakubov, Rebecca
AU  - Yakubov R
AD  - Ms. Marushchak and Dr. Goldenberg are with the Icahn School of Medicine at Mount 
      Sinai in New York, New York.
AD  - Ms. Rose Yakubov and Ms. Rebecca Yakubov are with McMaster University in 
      Hamilton, Ontario, Canada.
FAU - Goldenberg, Gary
AU  - Goldenberg G
AD  - Ms. Marushchak and Dr. Goldenberg are with the Icahn School of Medicine at Mount 
      Sinai in New York, New York.
AD  - Ms. Rose Yakubov and Ms. Rebecca Yakubov are with McMaster University in 
      Hamilton, Ontario, Canada.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Clin Aesthet Dermatol
JT  - The Journal of clinical and aesthetic dermatology
JID - 101518173
PMC - PMC8794486
OTO - NOTNLM
OT  - JAK inhibitors
OT  - Psoriasis
OT  - novel oral treatment
COIS- DISCLOSURES: Dr. Goldenberg is a consultant for Abbvie, Amgen, Celgene, Janssen, 
      Novartis, Lilly, BMS, and Pfizer, and a speaker for Abbvie, Amgen, Lilly, and 
      Novartis. Ms. Yakubov, Ms. Yakubov, and Ms. Marushchak have no conflicts of 
      interest to disclose.
EDAT- 2022/02/01 06:00
MHDA- 2022/02/01 06:01
PMCR- 2021/12/01
CRDT- 2022/01/31 05:58
PHST- 2022/01/31 05:58 [entrez]
PHST- 2022/02/01 06:00 [pubmed]
PHST- 2022/02/01 06:01 [medline]
PHST- 2021/12/01 00:00 [pmc-release]
PST - ppublish
SO  - J Clin Aesthet Dermatol. 2021 Dec;14(12):55-63.